Source: Health Products Regulatory Authority (IE) Revision Year: 2021 Publisher: Accord Healthcare Ireland Ltd., Euro House, Euro Business Park, Little Island, Cork T45 K857, Ireland
Pharmacotherapeutic group: Fluoroquinolones
ATC code: J01MA02
As a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.
Efficacy mainly depends on the relation between the maximum concentration in serum (Cmax) and the minimum inhibitory concentration (MIC) of ciprofloxacin for a bacterial pathogen and the relation between the area under the curve (AUC) and the MIC.
In-vitro resistance to ciprofloxacin can be acquired through a stepwise process by target site mutations in both DNA gyrase and topoisomerase IV. The degree of cross-resistance between ciprofloxacin and other fluoroquinolones that results is variable. Single mutations may not result in clinical resistance, but multiple mutations generally result in clinical resistance to many or all active substances within the class.
Impermeability and/or active substance efflux pump mechanisms of resistance may have a variable effect on susceptibility to fluoroquinolones, which depends on the physiochemical properties of the various active substances within the class and the affinity of transport systems for each active substance. All in-vitro mechanisms of resistance are commonly observed in clinical isolates. Resistance mechanisms that inactivate other antibiotics such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may affect susceptibility to ciprofloxacin. Plasmid-mediated resistance encoded by qnr-genes has been reported.
Breakpoints separate susceptible strains from strains with intermediate susceptibility and the latter from resistant strains:
EUCAST Recommendations
| Microorganisms | Susceptible | Resistant |
|---|---|---|
| Enterobacteriaceae | S ≤ 0.25 mg/L | R > 0.5 mg/L |
| Salmonella spp. | S < 0.06mg/L | R > 0.06mg/L |
| Pseudomonas spp. | S ≤ 0.5 mg/L | R > 0.5 mg/L |
| Acinetobacter spp. | S ≤ 1 mg/L | R > 1 mg/L1 |
| Staphylococcus spp. | S ≤ 1 mg/L | R > 1 mg/L |
| Haemophilus influenzae | S ≤ 0.5 mg/L | R > 0.6 mg/L |
| Moraxella catarrhalis | S <0.125mg/L | R > 0.125mg/L |
| Neisseria gonorrhoeae | S ≤ 0.03 mg/L | R > 0.06 mg/L |
| Neisseria meningitidis | S ≤ 0.03 mg/L | R > 0.03 mg/L |
| Non-species-related breakpoints* | S ≤ 0.5 mg/L | R > 0.5 mg/L |
1 Staphylococcus spp. –breakpoints for ciprofloxacin relate to high dose therapy.
* Non-species-related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and not for those species where susceptibility testing is not recommended.
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.
Groupings of relevant species according to ciprofloxacin susceptibility (for Streptococcus species see section 4.4):
| COMMONLY SUSCEPTIBLE SPECIES |
| Aerobic Gram-positive micro-organisms |
| Bacillus anthracis1 |
| Aerobic Gram-negative micro-organisms |
| Aeromonas spp. |
| Brucella spp. |
| Citrobacter koseri |
| Francisella tularensis |
| Haemophilus ducreyi |
| Haemophilus influenzae* |
| Legionella spp. |
| Moraxella catarrhalis* |
| Neisseria meningitidis |
| Pasteurella spp. |
| Salmonella spp.* |
| Shigella spp.* |
| Vibrio spp. |
| Yersinia pestis |
| Anaerobic micro-organisms |
| Mobiluncus |
| Other micro-organisms |
| Chlamydia trachomatis$ |
| Chlamydia pneumoniae$ |
| Mycoplasma hominis$ |
| Mycoplasma pneumoniae$ |
| SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM |
| Aerobic Gram-positive micro-organisms |
| Enterococcus faecalis$ |
| Staphylococcus spp.2* |
| Aerobic Gram-negative micro-organisms |
| Acinetobacter baumannii+ |
| Burkholderia cepacia+* |
| Campylobacter spp.+* |
| Citrobacter freundii* |
| Enterobacter aerogenes |
| Enterobacter cloacae* |
| Escherichia coli* |
| Klebsiella oxytoca |
| Klebsiella pneumoniae* |
| Morganella morganii* |
| Neisseria gonorrhoeae* |
| Proteus mirabilis* |
| Proteus vulgaris* |
| Providencia spp. |
| Pseudomonas aeruginosa* |
| Pseudomonas fluorescens |
| Serratia marcescens* |
| Anaerobic micro-organisms |
| Peptostreptococcus spp. |
| Propionibacterium acnes |
| INHERENTLY RESISTANT ORGANISMS |
| Aerobic Gram-positive micro-organisms |
| Actinomyces |
| Enteroccus faecium |
| Listeria monocytogenes |
| Aerobic Gram-negative micro-organisms |
| Stenotrophomonas maltophilia |
| Anaerobic micro-organisms |
| Excepted as listed above |
| Other micro-organisms |
| Mycoplasma genitalium |
| Ureaplasma urealitycum |
* Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications
+ Resistance rate ≥50% in one or more EU countries
$ Natural Intermediate susceptibility in the absence of acquired mechanism of resistance
1 Studies have been conducted in experimental animal infections due to inhalations of Bacillus anthracis spores; these studies reveal that antibiotics starting early after exposition avoid the occurrence of the disease if the treatment is made up to the decrease of the number of spores in the organism under the infective dose. The recommended use in human subjects is based primarily on in-vitro susceptibility and on animal experimental data together with limited human data. Two-month treatment duration in adults with oral ciprofloxacin given at the following dose, 500 mg bid, is considered as effective to prevent anthrax infection in humans. The treating physician should refer to national and/or international consensus documents regarding treatment of anthrax.
2 Methicillin-resistant S. aureus very commonly express co-resistance to fluoroquinolones. The rate of resistance to methicillin is around 20 to 50% among all staphylococcal species and is usually higher in nosocomial isolates.
Following oral administration of single doses of 250 mg, 500 mg, and 750 mg of ciprofloxacin tablets, ciprofloxacin is absorbed rapidly and extensively, mainly from the small intestine, reaching maximum serum concentrations 1-2 hours later. Single doses of 100-750 mg produced dose-dependent maximum serum concentrations (Cmax) between 0.56 and 3.7 mg/L.
Serum concentrations increase proportionately with doses up to 1000 mg.
The absolute bioavailability is approximately 70-80%.
A 500 mg oral dose given every 12 hours has been shown to produce an area under the serum concentration-time curve (AUC) equivalent to that produced by an intravenous infusion of 400 mg ciprofloxacin given over 60 minutes every 12 hours.
Protein binding of ciprofloxacin is low (20-30%). Ciprofloxacin is present in plasma largely in a nonionised form and has a large steady state distribution volume of 2-3 L/kg body weight. Ciprofloxacin reaches high concentrations in a variety of tissues such as lung (epithelial fluid, alveolar macrophages, biopsy tissue), sinuses, inflamed lesions (cantharides blister fluid), and the urogenital tract (urine, prostate, endometrium) where total concentrations exceeding those of plasma concentrations are reached.
Low concentrations of four metabolites have been reported, which were identified as: desethyleneciprofloxacin (M1), sulphociprofloxacin (M2), oxociprofloxacin (M3) and formylciprofloxacin (M4). The metabolites display in-vitro antimicrobial activity but to a lower degree than the parent compound.
Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.
Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally. The serum elimination half-life in subjects with normal renal function is approximately 4-7 hours.
| Excretion of ciprofloxacin (% of dose) | ||
|---|---|---|
| Oral Administration | ||
| Urine | Faeces | |
| Ciprofloxacin | 44.7 | 25.0 |
| Metabolites (M1 - M4) | 11.3 | 7.5 |
Renal clearance is between 180-300 mL/kg/h and the total body clearance is between 480-600 mL/kg/h. Ciprofloxacin undergoes both glomerular filtration and tubular secretion. Severely impaired renal function leads to increased half lives of ciprofloxacin of up to 12 h.
Non-renal clearance of ciprofloxacin is mainly due to active trans-intestinal secretion and metabolism. 1% of the dose is excreted via the biliary route. Ciprofloxacin is present in the bile in high concentrations.
The pharmacokinetic data in paediatric patients are limited. In a study in children Cmax and AUC were not age-dependent (above one year of age). No notable increase in Cmax and AUC upon multiple dosing (10 mg/kg three times daily) was observed.
In 10 children with severe sepsis Cmax was 6.1 mg/L (range 4.6-8.3 mg/L) after a 1-hour intravenous infusion of 10 mg/kg in children aged less than 1 year compared to 7.2 mg/L (range 4.7-11.8 mg/L) for children between 1 and 5 years of age. The AUC values were 17.4 mg*h/L (range 11.8-32.0 mg*h/L) and 16.5 mg*h/L (range 11.0-23.8 mg*h/L) in the respective age groups.
These values are within the range reported for adults at therapeutic doses. Based on population pharmacokinetic analysis of paediatric patients with various infections, the predicted mean half-life in children is approx. 4-5 hours and the bioavailability of the oral suspension ranges from 50 to 80%.
Non-clinical data reveal no special hazards for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential, or toxicity to reproduction.
Like a number of other quinolones, ciprofloxacin is phototoxic in animals at clinically relevant exposure levels.
Data on photomutagenicity/photocarcinogenicity show a weak photomutagenic or phototumorigenic effect of ciprofloxacin in-vitro and in animal experiments. This effect was comparable to that of other gyrase inhibitors.
As reported for other gyrase inhibitors, ciprofloxacin causes damage to the large weight-bearing joints in immature animals. The extent of the cartilage damage varies according to age, species and dose; the damage can be reduced by taking the weight off the joints. Studies with mature animals (rat, dog) revealed no evidence of cartilage lesions. In a study in young beagle dogs, ciprofloxacin caused severe articular changes at therapeutic doses after two weeks of treatment, which were still observed after 5 months.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
